Complete financial analysis of FibroBiologics, Inc. Common Stock (FBLG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of FibroBiologics, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- Royal Gold, Inc. (0KXS.L) Income Statement Analysis – Financial Results
- Liaoning Kelong Fine Chemical,Inc. (300405.SZ) Income Statement Analysis – Financial Results
- iSTART-TEK INC. (6786.TWO) Income Statement Analysis – Financial Results
- Helio S.A. (HEL.WA) Income Statement Analysis – Financial Results
- Ameriprise Financial, Inc. (AMP) Income Statement Analysis – Financial Results
FibroBiologics, Inc. Common Stock (FBLG)
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 437.00K | 94.00K | 0.00 | 0.00 |
| Gross Profit | -437.00K | -94.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.37M | 1.15M | 521.00K | 669.00K |
| General & Administrative | 5.84M | 3.32M | 1.06M | 500.00K |
| Selling & Marketing | 685.00K | -94.00K | 0.00 | 0.00 |
| SG&A | 6.52M | 3.23M | 1.06M | 500.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.89M | 4.37M | 1.58M | 1.17M |
| Cost & Expenses | 8.89M | 4.47M | 1.58M | 1.17M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 147.00K | 654.00K | 4.00K | 0.00 |
| Depreciation & Amortization | 437.00K | 94.00K | 0.00 | 1.17M |
| EBITDA | -15.90M | -4.37M | -1.58M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.89M | -4.47M | -1.58M | -1.17M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -7.60M | -654.00K | -4.00K | 0.00 |
| Income Before Tax | -16.49M | -5.12M | -1.58M | -1.17M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -16.49M | -5.12M | -1.58M | -1.17M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.59 | -0.16 | -0.05 | -0.13 |
| EPS Diluted | -0.68 | -0.16 | -0.05 | -0.13 |
| Weighted Avg Shares Out | 32.49M | 32.49M | 32.49M | 8.75M |
| Weighted Avg Shares Out (Dil) | 28.23M | 32.49M | 32.49M | 8.75M |
FibroBiologics Announces Three United States Patents for Fibroblast Technology
FibroBiologics Announces Three Japanese Patents on Fibroblast Technology
U.S. IPO Weekly Recap: Amer Sports' Billion-Dollar U.S. IPO Leads A Week Of Large Listings
FibroBiologics Announces Direct Listing on NASDAQ Under the Stock Ticker FBLG
U.S. IPO Weekly Recap: Reinsurance And CAR T Therapies Lead A 3 IPO Week
Source: https://incomestatements.info
Category: Stock Reports